Assessment of micafungin dosage regimens against Candida spp. in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation

References

• Science M, Robinson PD, MacDonald T, et al. Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. Pediatr Blood Cancer. 2014;61(3):393–400.
   PubMed Web of Science ®Google Scholar
• Barnes PD, Marr KA. Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. Br J Haematol. 2007;139(4):519–531.
   PubMed Web of Science ®Google Scholar
• Puerta-Alcalde P, Garcia-Vidal C. Changing epidemiology of invasive fungal disease in allogeneic hematopoietic stem cell transplantation. JoF. 2021;7(10):848.
   Google Scholar
• Bhatti Z, Shaukat A, Almyroudis NG, et al. Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients. Mycopathologia. 2006;162(1):1–15.
   PubMed Web of Science ®Google Scholar
• Kim BK, Choi JY, Hong KT, et al. Prospective study on prophylactic micafungin sodium against invasive fungal disease during neutropenia in pediatric & adolescent patients undergoing autologous hematopoietic stem cell transplantation. Children (Basel). 2022;9(3):372.
   PubMed Web of Science ®Google Scholar
• Lewis RE. Current concepts in antifungal pharmacology. Mayo Clin Proc. 2011;86(8):805–817.
   PubMed Web of Science ®Google Scholar
• Girmenia C, Iori AP. Safety and interactions of new antifungals in stem cell transplant recipients. Expert Opin Drug Saf. 2012;11(5):803–818.
   PubMed Web of Science ®Google Scholar
• Joseph JM, Jain R, Danziger LH. Micafungin: a new echinocandin antifungal. Pharmacotherapy. 2007;27(1):53–67.
   PubMed Web of Science ®Google Scholar
• Hatano K, Morishita Y, Nakai T, et al. Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus. J Antibiot (Tokyo). 2002;55(2):219–222.
   PubMed Web of Science ®Google Scholar
• Chandra S, Fukuda T, Mizuno K, et al. Micafungin antifungal prophylaxis in children undergoing HSCT: can we give higher doses, less frequently? A pharmacokinetic study. J Antimicrob Chemother. 2018;73(6):1651–1658.
   PubMed Web of Science ®Google Scholar
• Carter NJ, Keating GM. Micafungin: a review of its use in the prophylaxis and treatment of invasive candida infections in pediatric patients. Paediatr Drugs. 2009;11(4):271–291.
   PubMedGoogle Scholar
• Lehrnbecher T. The clinical management of invasive mold infection in children with cancer or undergoing hematopoietic stem cell transplantation. Expert Rev anti Infect Ther. 2019;17(7):489–499.
   PubMed Web of Science ®Google Scholar
• Alqahtani S, Alfarhan A, Alsultan A, et al. Assessment of micafungin dosage regimens in patients with cancer using pharmacokinetic/pharmacodynamic modeling and Monte Carlo simulation. Antibiotics (Basel). 2021;10(11):1363.
   PubMed Web of Science ®Google Scholar
• Wasmann RE, Muilwijk EW, Burger DM, et al. Clinical pharmacokinetics and pharmacodynamics of micafungin. Clin Pharmacokinet. 2018;57(3):267–286.
   PubMed Web of Science ®Google Scholar
• Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother. 2005;49(8):3317–3324.
   PubMed Web of Science ®Google Scholar
• Undre NA, Stevenson P, Freire A, et al. Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia. Pediatr Infect Dis J. 2012;31(6):630–632.
   PubMed Web of Science ®Google Scholar
• Albano E, Azie N, Roy M, et al. Pharmacokinetic and safety profiles of repeated-dose prophylactic micafungin in children and adolescents undergoing hematopoietic stem cell transplantation. J Pediatr Hematol Oncol. 2015;37(1):e45–e50.
   PubMed Web of Science ®Google Scholar
• Andes D, Diekema DJ, Pfaller MA, et al. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against candida species. Antimicrob Agents Chemother. 2010;54(6):2497–2506.
   PubMed Web of Science ®Google Scholar
• Mouton JW, Dudley MN, Cars O, et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother. 2005;55(5):601–607.
   PubMed Web of Science ®Google Scholar
• Masterton RG, Kuti JL, Turner PJ, et al. The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe. J Antimicrob Chemother. 2005;55(1):71–77.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Micafungin information (micafungin sodium). 2021 [cited 2021 July 30]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212125s000lbl.pdf.
   Google Scholar
• European Medicines Agency. Summary of product characteristics: mycamine. 2022 [cited 2022 January 4]. https://www.ema.europa.eu/en/documents/product-information/mycamine-epar-product-information_en.pdf.
   Google Scholar
• Xu G, Zhu L, Liao S, et al. Assessment of echinocandin regimens by pharmacokinetic/pharmacodynamic analysis against candida spp. in paediatric patients. Int J Antimicrob Agents. 2015;46(6):631–641.
   PubMed Web of Science ®Google Scholar
• Zhong S, Zhu X, Zhao L, et al. Optimization of micafungin dosage for chinese patients with sepsis in the intensive care unit based on a population pharmacokinetic-pharmacodynamic analysis. Pharm Res. 2021;38(1):67–77.
   PubMed Web of Science ®Google Scholar
• Scott LJ. Micafungin: a review in the prophylaxis and treatment of invasive candida infections in paediatric patients. Paediatr Drugs. 2017;19(1):81–90.
   PubMed Web of Science ®Google Scholar
• Hiemenz J, Cagnoni P, Simpson D, et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother. 2005;49(4):1331–1336.
   PubMed Web of Science ®Google Scholar